New weight loss pill enters early human testing
NCT ID NCT06562907
First seen Mar 25, 2026 · Last updated May 16, 2026 · Updated 9 times
Summary
This early-stage study tests a new oral drug called GS-4571 for weight management. Researchers will give single or multiple doses to healthy people, non-diabetic obese individuals, and non-obese people with type 2 diabetes. The main goals are to see how the drug moves through the body, how safe it is, and whether food or acid-reducing medicines affect it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
-
ICON Early Phase Services, LLC
RECRUITINGSan Antonio, Texas, 78209, United States
-
Qps-Mra, Llc.
RECRUITINGMiami, Florida, 33143, United States
Conditions
Explore the condition pages connected to this study.